ICG-<wbr/>001

ICG-001

CAT N°: 16257
Price:

From 54.00 45.90

ICG-001 is a small molecule inhibitor of ?-catenin/cyclic AMP responsive element binding protein (CREB) binding protein (CBP)-mediated transcription (IC50 = 3 µM).{26952} By binding CBP, thus blocking interaction with ?-catenin, it selectively induces apoptosis in transformed colon cells but not in normal cells and prevents the growth of colon carcinoma cells at 25 µM in vitro.{26952,26951} ICG-001 has been used to specifically disrupt the ?-catenin pathway in studying epithelial-mesenchymal transition during pulmonary fibrosis.{26949,26953} Additionally, ICG-001 disruption of Wnt/?-catenin signaling has been studied in the context of regulating cancer stem cells.{26950}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • (6S,9aS)-hexahydro-6-[(4-hydroxyphenyl)methyl]-8-(1-naphthalenylmethyl)-4,7-dioxo-N-(phenylmethyl)-2H-pyrazino[1,2-a]pyrimidine-1(6H)-carboxamide
  • Correlated keywords
    • inhibitors Wnts ?-catenins cyclic AMPs responsive elements bindings proteins binding protein CBP transcriptions cancer pulmonary fibrosis cancers stems cells 847591-62-2 868774-16-7 721457-27-8 1402835-92-0 ICG001 ICG 001 antagonists Wnt/?-catenin Wnt/? catenins ? TCF-mediated TCF mediated binds element-binding inhibits inhibitions intracellular signaling transductions biochemicals research small molecules cyclic AMP cAMP blocks blocking interactions selectively induces induced apoptosis transformed colon prevents prevention growths carcinomas in vitro disrupts disruptions epithelial-mesenchymal epithelial mesenchymal transitions pulmonary fibrosis regulations regulating
  • Product Overview:
    ICG-001 is a small molecule inhibitor of ?-catenin/cyclic AMP responsive element binding protein (CREB) binding protein (CBP)-mediated transcription (IC50 = 3 µM).{26952} By binding CBP, thus blocking interaction with ?-catenin, it selectively induces apoptosis in transformed colon cells but not in normal cells and prevents the growth of colon carcinoma cells at 25 µM in vitro.{26952,26951} ICG-001 has been used to specifically disrupt the ?-catenin pathway in studying epithelial-mesenchymal transition during pulmonary fibrosis.{26949,26953} Additionally, ICG-001 disruption of Wnt/?-catenin signaling has been studied in the context of regulating cancer stem cells.{26950}

We also advise you